Literature DB >> 11314037

Cytotoxicity of Tumor necrosis factor related apoptosis-inducing ligand towards Ewing's sarcoma cell lines.

A Kumar1, A Jasmin, M T Eby, P M Chaudhary.   

Abstract

Death ligands of the Tumor Necrosis Factor (TNF) family are known to induce apoptosis upon binding to their cognate receptors. However, the clinical utility of these cytokines as anticancer agents has been limited due to unacceptable toxicity. TRAIL is a recently isolated death ligand that possesses selective anti-tumor activity against a number of cancer cell lines without significant systemic toxicity. In this report we present evidence that cell lines derived from Ewing's Sarcoma (ES) are uniformly sensitive to TRAIL-mediated apoptosis. Furthermore, unlike TNF-alpha, treatment with TRAIL fails to induce the anti-apoptotic and pro-inflammatory NF-kappaB pathway in the ES cell lines. Our results suggest that TRAIL may prove to be a useful agent for the treatment of Ewing's sarcoma and related peripheral neuroectodermal tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11314037     DOI: 10.1038/sj.onc.1204154

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.

Authors:  Gaëlle Picarda; Valérie Trichet; Stéphane Téletchéa; Dominique Heymann; Françoise Rédini
Journal:  Am J Cancer Res       Date:  2011-10-09       Impact factor: 6.166

Review 2.  Emerging chemotherapeutic strategies and the role of treatment stratification in Ewing sarcoma.

Authors:  Beatrice M Seddon; Jeremy S Whelan
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

3.  Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program.

Authors:  Malcolm A Smith; Christopher L Morton; E Anders Kolb; Richard Gorlick; Stephen T Keir; Hernan Carol; Richard Lock; Min H Kang; C Patrick Reynolds; John M Maris; Amy E Watkins; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2010-02       Impact factor: 3.167

4.  Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity.

Authors:  Andrej Lissat; Thomas Vraetz; Maria Tsokos; Ruth Klein; Matthias Braun; Nino Koutelia; Paul Fisch; Maria E Romero; Lauren Long; Peter Noellke; Crystal L Mackall; Charlotte M Niemeyer; Udo Kontny
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

5.  Fas/Fas ligand regulation mediates cell death in human Ewing's sarcoma cells treated with melatonin.

Authors:  G García-Santos; V Martin; J Rodríguez-Blanco; F Herrera; S Casado-Zapico; A M Sánchez-Sánchez; I Antolín; C Rodríguez
Journal:  Br J Cancer       Date:  2012-03-01       Impact factor: 7.640

Review 6.  Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma.

Authors:  Xing Dai; Wei Ma; Xijing He; Rajiv Kumar Jha
Journal:  Med Sci Monit       Date:  2011-08

7.  Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma.

Authors:  Zhigang Kang; Shi-Yong Sun; Liang Cao
Journal:  ISRN Oncol       Date:  2012-04-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.